Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation

Publication

Neurology

Author(s)

Laura L. Ekblad, MD, Jarkko Johansson, PhD, Semi Helin, MSc, Matti Viitanen, PhD, Hanna Laine, PhD,
Pauli Puukka, MSocSc, Antti Jula, PhD, and Juha O. Rinne, PhD

Abstract

Objective
To examine whether midlife insulin resistance is an independent risk factor for brain amyloid
accumulation in vivo after 15 years, and whether this risk is modulated by APOE e4 genotype.

Methods
This observational study examined 60 elderly volunteers without dementia (mean age at
baseline 55.4 and at follow-up 70.9 years, 55.5% women) from the Finnish population-based,
nationwide Health2000 study with [11C]Pittsburgh compound B–PET imaging in 2014–2016.
The participants were recruited according to their homeostatic model assessment of insulin
resistance (HOMA-IR) values in the year 2000, and their APOE e4 genotype. The exposure
group (IR+, n = 30) consisted of individuals with HOMA-IR >2.17 at baseline (highest tertile of
the Health2000 study population), and the control group (IR−, n = 30) consisted of individuals
with HOMA-IR

Date

April 10, 2018

View study